Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Inactivation of DNA Polymerase Theta (PolΘ) Is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies - Potential Clinical Applications

Bac Viet Le, Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Marie-Christine Caron, George Vassiliou, Malgorzata Gozdecka, Zayd Haydar, Gurushankar Chandramouly, Emir Hadzijusufovic, Wolfgang R. Sperr, Richard Pomerantz, Peter Valent, Jean-Yves Masson, Gaorav Gupta, Grant A Challen, Tomasz Skorski

Blood (2023) 142 (Supplement 1): 580.

https://doi.org/10.1182/blood-2023-174333

Published: 2023

Journal Articles

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Blood (2023) 141 (19): 2372–2389.

https://doi.org/10.1182/blood.2022018428

Published: 2023

Includes: Supplemental data

Journal Articles

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Blood (2022) 140 (Supplement 1): 2972–2974.

https://doi.org/10.1182/blood-2022-156458

Published: 2022

Journal Articles

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Yueksel Filik, Karin Bauer, Barbara Peter, Emir Hadzijusufovic, Georg Greiner, Nadine Witzeneder, Gregor Hoermann, Karoline V. Gleixner, Wolfgang R. Sperr, Peter Valent

Blood (2021) 138 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2021-152415

Published: 2021

Journal Articles

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Blood (2021) 137 (2): 238–247.

https://doi.org/10.1182/blood.2020006157

Published: 2021

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Massimiliano Bonifacio, MD, Patrizia Bonadonna, MD, Hanneke Oude Elberink, MD, Björn van Anrooij, MD, Aleksandra Górska, MD, Magdalena Lange, MD, Emir Hadzijusufovic, DVM, Luigi Scaffidi, Ilaria Tanasi, MD, Cecelia Perkins, Virginia Valeria Ferretti, Anja Illerhaus, PhD, Thilo Jakob, MD, Roberta Parente, MD, Mohamad Jawhar, MD, Francesca Caroppo, MD, Alexander Zink, MD, Alex Kilbertus, MD, Akif Selim Yavuz, MD, Michael Doubek, MD PhD, Hans Hagglund, MD PhD, Jens P. Panse, MD, Vito Sabato, MD PhD, Elisabeth Aberer, MD, Nadja Jaekel, MD, Peter Vandenberghe, MD PhD, David Fuchs, MD, Knut Brockow, MD, Anna Belloni Fortina, MD, Andreas Reiter, MD, Massimo Triggiani, MD, Khalid Shoumariyeh, MD, Karin Hartmann, MD, Chiara Elena, Olivier Hermine, MD PhD, Jason Gotlib, MD, Marek Niedoszytko, MD, Hanneke Kluin-Nelemans, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Roberta Zanotti, MD

Blood (2017) 130 (Supplement 1): 4200.

https://doi.org/10.1182/blood.V130.Suppl_1.4200.4200

Published: 2017

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Mathias A Schneeweiss, MD, Barbara Peter, DVM, Katharina Blatt, MSc,PhD, Daniela Berger, Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Karoline V Gleixner, MD, Peter Valent, MD

Blood (2016) 128 (22): 1965.

https://doi.org/10.1182/blood.V128.22.1965.1965

Published: 2016

Journal Articles

Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib

Emir Hadzijusufovic, DVM, Rudolf Kirchmair, MD, Markus Theurl, MD, Susanne Gamperl, MSc, Daniela Lener, Clemens Gutmann, Ursula Stanzl, Andrijana Kirsch, MD, Sasa Frank, PhD, Peter Valent, MD

Blood (2016) 128 (22): 1883.

https://doi.org/10.1182/blood.V128.22.1883.1883

Published: 2016

Journal Articles

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Katharina Blatt, Sabine Cerny-Reiterer, Juliana Schwaab, Karl Sotlar, Gregor Eisenwort, Gabriele Stefanzl, Gregor Hoermann, Matthias Mayerhofer, Mathias Schneeweiss, Sylvia Knapp, Thomas Rülicke, Emir Hadzijusufovic, Karin Bauer, Dubravka Smiljkovic, Michael Willmann, Andreas Reiter, Hans-Peter Horny, Peter Valent

Blood (2015) 126 (26): 2832–2841.

https://doi.org/10.1182/blood-2015-03-637728

Published: 2015

Includes: Supplemental data

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Alexandra Keller, MSc, Barbara Peter, DVM, Johannes Zuber, MD PhD, Philipp Bernhard Staber, MD PhD, Peter Bettelheim, MD, Peter Valent, MD, Emir Hadzijusufovic, DVM

Blood (2015) 126 (23): 2829.

https://doi.org/10.1182/blood.V126.23.2829.2829

Published: 2015

Journal Articles

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Peter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, Dominik Wolf, Delphine Rea, Philipp le Coutre

Blood (2015) 125 (6): 901–906.

https://doi.org/10.1182/blood-2014-09-594432

Published: 2015

Includes: Supplemental data

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Blood (2014) 124 (1): 111–120.

https://doi.org/10.1182/blood-2013-10-534685

Published: 2014

Includes: Supplemental data

Journal Articles

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Ghaith Wedeh, Emir Hadzijusufovic, DVM, Sabine Cerny-Reiterer, D.V.M, Harald Herrmann, M.D., Katharina Blatt, MSc, Ph.D., Gregor Eisenwort, M.D., Ph.D, Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Leonhard Müllauer, M.D., Christopher R. Vakoc, M.D., Ph.D., James E Bradner, MD, Hans-Peter Horny, MD, Michael Willmann, D.V.M., Johannes Zuber, MD, Michel Arock, PharmD, Ph.D, Peter Valent

Blood (2013) 122 (21): 3747.

https://doi.org/10.1182/blood.V122.21.3747.3747

Published: 2013

Journal Articles

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Katharina Blatt, MSc, Ph.D., Sabine Cerny-Reiterer, D.V.M, Karl Sotlar, M.D., Schwaab Juliana, M.D., Gregor Hoermann, M.D., Ph.D., Matthias Mayerhofer, M.D., Emir Hadzijusufovic, DVM, Michael Willmann, D.V.M., Andreas Reiter, MD, Hans-Peter Horny, MD, Peter Valent

Blood (2013) 122 (21): 3773.

https://doi.org/10.1182/blood.V122.21.3773.3773

Published: 2013

Journal Articles

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Gregor Hoermann, M.D., Ph.D., Karoline V. Gleixner, M.D., Graziella E. Dinu, B.Sc., Georg Greiner, Friedrich Wimazal, M.D., Emir Hadzijusufovic, DVM, Gerlinde Mitterbauer, M.D., Christine Mannhalter, Ph.D., Peter Valent, Wolfgang R Sperr, M.D.

Blood (2013) 122 (21): 4052.

https://doi.org/10.1182/blood.V122.21.4052.4052

Published: 2013

NARROW

Inactivation of DNA Polymerase Theta (PolΘ) Is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies - Potential Clinical Applications

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only